1 Study Matches
A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
A study of the safety of levatinib with everolimus for children with solid tumors and central nervous system tumors that returned or did not respond to previous treatment.
Inclusion Criteria:You have Ewing sarcoma/pPNET or Rhabdomyosarcoma or a HGG that has come back or is not responding to treatment
Your cancer can be measured by certain criteria
You are ≥2 years and ≤21 years of age
Exclusion Criteria:You have lymphoma
You have a wound or injury that won't heal